4.7 Article

Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate

Journal

SCIENTIFIC REPORTS
Volume 6, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/srep26245

Keywords

-

Funding

  1. Intramural Research Program of NIH
  2. National Cancer Institute (NCI) [Z01 BC010891, ZIA BC010891]
  3. NIH [HL094463-05, GM102137]

Ask authors/readers for more resources

Heparan sulfate (HS) is a polysaccharide known to modulate many important biological processes, including Wnt signaling. However, the biochemical interaction between HS and Wnt molecules is not well characterized largely due to the lack of suitable methods. To determine the Wnt binding domain in HS, we used a Wnt signaling-inhibitory antibody (HS20) and a panel of synthetic HS oligosaccharides with distinct lengths and sulfation modifications. We found that the binding of HS20 to heparan sulfate required sulfation at both the C2 position (2-O-sulfation) and C6 position (6-O-sulfation). The oligosaccharides with the greatest competitive effect for HS20 binding were between six and eight saccharide residues in length. Additionally, a four residue-long oligosaccharide could also be recognized by HS20 if an additional 3-O-sulfation modification was present. Furthermore, similar oligosaccharides with 2-O, 6-O and 3-O-sulfations showed inhibition for Wnt activation. These results have revealed that HS20 and Wnt recognize a HS structure containing IdoA2S and GlcNS6S, and that the 3-O-sulfation in GlcNS6S3S significantly enhances the binding of both HS20 and Wnt. This study provides the evidence for identifying the Wnt binding domain in HS and suggests a therapeutic approach to target the interaction of Wnt and HS in cancer and other diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biology

R-spondins engage heparan sulfate proteoglycans to potentiate WNT signaling

Ramin Dubey, Peter van Kerkhof, Ingrid Jordens, Tomas Malinauskas, Ganesh Pusapati, Joseph K. Mckenna, Dan Li, Jan E. Carette, Mitchell Ho, Christian Siebold, Madelon Maurice, Andres M. Lebensohn, Rajat Rohatgi

ELIFE (2020)

Review Cell Biology

The Role of Glypicans in Cancer Progression and Therapy

Nan Li, Madeline R. Spetz, Mitchell Ho

JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2020)

Article Multidisciplinary Sciences

Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells

Panpan Meng, Yi-Fan Zhang, Wangli Zhang, Xin Chen, Tong Xu, Sheng Hu, Xinjun Liang, Mingqian Feng, Xiaoqing Yang, Mitchell Ho

Summary: The study revealed FAT1 as a novel interacting protein of GPC3, with both showing elevated expression in HCC cells, being up-regulated under hypoxia conditions, and regulating the expression of EMT-related genes to promote HCC cell migration.

SCIENTIFIC REPORTS (2021)

Article Multidisciplinary Sciences

Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia

Xue Yan Cui, Geir Erland Tjonnfjord, Sandip M. Kanse, Anders Erik Astrup Dahm, Nina Iversen, Christiane Filion Myklebust, Ling Sun, Zhong Xing Jiang, Thor Ueland, James J. Campbell, Mitchell Ho, Per Morten Sandset

Summary: Plasma TFPI levels are higher in CLL patients compared to healthy controls, especially in those with advanced disease. TFPI enhances CXCL12-mediated migration of CLL cells through increased expression of the CXCR7 receptor. TFPI, which co-localizes with GPC3, plays a crucial role in regulating CXCR7 expression and TEM.

SCIENTIFIC REPORTS (2021)

Review Pharmacology & Pharmacy

Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3

Nan Li, Madeline R. Spetz, Dan Li, Mitchell Ho

Summary: Cancer immunotherapies have revolutionized the treatment of adult malignancies and are now being translated to pediatric oncology. Successful immunotherapeutic agents for pediatric cancers include chimeric antigen receptor T-cell therapy, bispecific antibodies targeting CD19, and anti-GD2 monoclonal antibody. Advancements in tumor immunology and genome profiling have led to the identification of new tumor-specific antigens, such as Glypican 2 (GPC2) and B7-H3 (CD276), which could have a positive impact on pediatric cancer treatment.

PHARMACOLOGY & THERAPEUTICS (2021)

Article Oncology

Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma

Luan Sun, Fang Gao, Zhanhui Gao, Lei Ao, Na Li, Sujuan Ma, Meng Jia, Nan Li, Peihua Lu, Beicheng Sun, Mitchell Ho, Shaochang Jia, Tong Ding, Wei Gao

Summary: This study constructed two types of CAR-T cells targeting different epitopes of GPC3 to investigate the influence of sGPC3 on the activation and cytotoxicity of CAR-T cells in vitro and in vivo. Results showed that sGPC3 significantly inhibited the release of cytokines and the cytotoxicity of anti-GPC3 CAR-T cells in vitro, and in mouse models sGPC3 expression in Hep3B xenograft tumors led to a worse response to CAR-T cell treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Review Cell Biology

Role of glypican-1 in regulating multiple cellular signaling pathways

Jiajia Pan, Mitchell Ho

Summary: Glypican-1 (GPC1) modulates various signaling pathways by interacting with pathway ligands and receptors, impacting the pathways' activation or inhibition based on specific GPC1 domain interactions with pathway components and cell surface context.

AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2021)

Review Oncology

T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy

Zhijian Duan, Mitchell Ho

Summary: Antibody-based immunotherapies have shown efficacy in cancer treatment, but their targets are limited. Research has shown that short peptides from intracellular targets could be potential immunotherapy targets. TCRm antibodies are a promising new direction, and future clinical studies will help further understand their mechanisms of action.

MOLECULAR CANCER THERAPEUTICS (2021)

Article Oncology

Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice

Xin Chen, Yanmin Chen, Rong Liang, Lanxin Xiang, Jingwen Li, Yuankui Zhu, Huixia He, Le Huang, Dianbao Zuo, Weihang Li, Xinjun Liang, Shuang Dong, Sheng Hu, Mitchell Ho, Mingqian Feng

Summary: This study investigated the efficacy of six GPC3-targeted bispecific antibodies for the treatment of HCC, and found that the hYP7-OKT3-hFc antibody was the most effective. Combination with the chemotherapeutic drug Irinotecan further enhanced the therapeutic effect.

MOLECULAR CANCER THERAPEUTICS (2022)

Article Oncology

A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer

Dan Li, Hejiao English, Jessica Hong, Tianyuzhou Liang, Glenn Merlino, Chi-Ping Day, Mitchell Ho

Summary: CAR-T cell therapy has shown great potential in treating hematological malignancies, but its efficacy in solid tumors is limited. In this study, the researchers developed a CAR-T therapy targeting PD-L1 and successfully treated breast cancer and liver cancer, while also inhibiting tumor metastasis.

MOLECULAR THERAPY-ONCOLYTICS (2022)

Article Oncology

GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling

Jiajia Pan, Nan Li, Alex Renn, Hu Zhu, Lu Chen, Min Shen, Matthew D. Hall, Min Qian, Ira Pastan, Mitchell Ho

Summary: The cell surface proteoglycan GPC1 is overexpressed in multiple types of human cancers, including pancreatic cancer. In this study, researchers constructed GPC1-targeted immunotoxins and found that these immunotoxins can inhibit pancreatic tumor growth. Combining the immunotoxin with irinotecan further enhanced its efficacy.

MOLECULAR CANCER THERAPEUTICS (2022)

Article Multidisciplinary Sciences

Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants

Jessica Hong, Hyung Joon Kwon, Raul Cachau, Catherine Z. Chen, Kevin John Butay, Zhijian Duan, Dan Li, Hua Ren, Tianyuzhou Liang, Jianghai Zhu, Venkata P. Dandey, Negin P. Martin, Dominic Esposito, Uriel Ortega-Rodriguez, Miao Xu, Mario J. Borgnia, Hang Xie, Mitchell Ho

Summary: The study constructed large dromedary camel VHH phage libraries and successfully isolated two high-affinity nanobodies that showed broad neutralization activity against SARS-CoV-2 and its variants. These nanobodies can be used for therapeutic purposes against COVID-19 variants, and the dromedary camel VHH phage libraries serve as a unique platform for rapidly isolating potent nanobodies against future emerging viruses.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Article Multidisciplinary Sciences

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin

Xiufen Liu, Masanori Onda, Nathan Watson, Raffit Hassan, Mitchell Ho, Tapan K. Bera, Junxia Wei, Anirban Chakraborty, Richard Beers, Qi Zhou, Asif Shajahan, Parastoo Azadi, Jingyu Zhan, Di Xia, Ira Pastan

Summary: Researchers have identified a monoclonal antibody that inhibits the shedding of the protein MSLN, which is highly expressed by cancer cells. The antibody binds to the protease-sensitive region of MSLN and CAR T cells produced with this antibody show superior antitumor activity.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Article Biochemical Research Methods

Preclinical testing of chimeric antigen receptor T cells in neuroblastoma mouse models

Nan Li, Rosa Nguyen, Carol J. Thiele, Mitchell Ho

Summary: This study presents neuroblastoma metastatic and orthotopic mouse models to aid in the translation of CAR T cell therapy research. Additionally, we have established an analysis pipeline for evaluating the efficacy and immunological characteristics of CAR T cells and tumor cells.

STAR PROTOCOLS (2021)

Article Cell Biology

CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice

Nan Li, Madeline B. Torres, Madeline R. Spetz, Ruixue Wang, Luyi Peng, Meijie Tian, Christopher M. Dower, Rosa Nguyen, Ming Sun, Chin-Hsien Tai, Natalia de Val, Raul Cachau, Xiaolin Wu, Stephen M. Hewitt, Rosandra N. Kaplan, Javed Khan, Brad St Croix, Carol J. Thiele, Mitchell Ho

Summary: The study utilized RNA sequencing analysis to identify high expression of GPC2 exons 3 and exons 7-10 in cancer but minimal expression in normal tissues. A monoclonal antibody CT3 was discovered and used to design CAR T cells for treating neuroblastoma. Genomic sequencing of T cells recovered from mice revealed potential CAR integration sites contributing to CART cell proliferation and persistence.

CELL REPORTS MEDICINE (2021)

No Data Available